课题基金 / 基金详情

Exenatide and Insulin Glargine Combination Therapy for the Preservation of Pancreatic Beta-cell Function in Early Type 2 Diabetes: A Randomized Controlled Trial

Exenatide and Insulin Glargine Combination Therapy for the Preservation of Pancreatic Beta-cell Function in Early Type 2 Diabetes: A Randomized Controlled Trial
艾塞那肽和甘精胰岛素联合治疗可保护早期 2 型糖尿病的胰腺 β 细胞功能:一项随机对照试验
批准号:
304783
负责人:
Retnakaran Ravi R
金额:
$26.73万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2014
资助国家:
加拿大
项目状态:
已结题
起止时间:
2014-03-01 至 2017-03-01

项目摘要

项目成果

Retnakaran Ravi R的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Currently, ~3 million Canadians are affected by type 2 diabetes (T2DM). The central problem in T2DM is an inability of the beta-cells of the pancreas to produce enough insulin for the body's needs. This so-called "beta-cell dysfunction" worsens over time
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Community-based Preconception Lifestyle Intervention to prevent Gestational Diabetes Mellitus in Women living in India
  • 批准号:
    494564
  • 项目类别:
    Operating Grants
  • 资助金额:
    $45.53万
  • 财政年份:
    2023
  • 负责人:
    Retnakaran Ravi R
  • 依托单位:
The Evolution of Diabetes Risk in Canadian Women following Glucose Intolerance in Pregnancy
  • 批准号:
    494175
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2023
  • 负责人:
    Retnakaran Ravi R
  • 依托单位:
Preconception Lifestyle Intervention by Community Health Workers for the Prevention of Gestational Diabetes Mellitus: A Randomized Clinical Trial
  • 批准号:
    461671
  • 项目类别:
    Operating Grants
  • 资助金额:
    $38.73万
  • 财政年份:
    2022
  • 负责人:
    Retnakaran Ravi R
  • 依托单位:
Collaborative Care Initiated Prior to Conception by Public Health Nurses for the Prevention of Gestational Diabetes Mellitus in Canadian Women
  • 批准号:
    461931
  • 项目类别:
    Operating Grants
  • 资助金额:
    $25.13万
  • 财政年份:
    2022
  • 负责人:
    Retnakaran Ravi R
  • 依托单位:
海外基金